BIOMAT Database Logo BIOMAT Database Logo

Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. 1993

Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Third Department of Internal Medicine, Mie University School of Medicine, Japan.

We quantified serum hepatitis C virus RNA titers and determined hepatitis C virus subtypes in chronic hepatitis C patients treated with interferon-beta to investigate relationships among serum ALT response, serum hepatitis C virus titer and hepatitis C virus subtype. Of 146 chronic hepatitis C patients who received interferon-beta therapy, 24 patients with sustained serum ALT normalization (complete responders) and 26 patients without serum ALT normalization (nonresponders) were randomly selected. Detection, typing and quantitation of hepatitis C virus were performed by means of the "single-tube" polymerase chain reaction method. Of the 24 complete responders, 21 (87.5%) became negative for hepatitis C virus RNA, whereas 21 (80.8%) of the 26 nonresponders remained positive. Hepatitis C virus infections with types I, II, III, IV, II + III and III + IV occurred in 0 (0%), 22 (51.2%), 10 (23.3%), 1 (2.3%), 7 (16.5%) and 3 (7.9%) patients, respectively. The mean pretreatment hepatitis C virus RNA titer of complete responders (0.4 +/- 2.0 x 10(4) CID50/ml) was significantly lower than that of nonresponders (3.8 +/- 4.5 x 10(4) CID50/ml) (p < 0.01). Regardless of HCV subtype, patients with more than 10(4) CID50/ml of HCV did not show serum ALT normalization, whereas complete serum ALT response was seen in most cases with less than 10(2) CID50/ml HCV. These results show that mixed infections with different hepatitis C virus subtypes appear to be more common than previously reported and that the pretreatment serum level of hepatitis C virus RNA is a more important predictor of outcome of interferon therapy than is virus genotype.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic

Related Publications

Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha.
January 1992, Hepatology (Baltimore, Md.),
Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
[Titration and genotyping of hepatitis C virus RNA in chronic hepatitis C patients treated with interferon].
February 1994, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Quantitation of hepatitis C virus RNA in plasma and peripheral blood mononuclear cells of patients with chronic hepatitis treated with interferon-alpha.
January 2000, Digestive diseases and sciences,
Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C.
June 1991, Hepatology (Baltimore, Md.),
Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Quantitative hepatitis C virus RNA and liver histology in chronic hepatitis C patients treated with interferon alfa.
January 1993, Gut,
Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study.
May 1997, Clinical and diagnostic virology,
Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Detection of hepatitis C virus RNA in serum and peripheral blood mononuclear cells in patients with chronic hepatitis C treated with interferon alpha.
November 1996, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa.
June 1996, Hepatology (Baltimore, Md.),
Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon.
May 1997, Journal of medical virology,
Y Kobayashi, and S Watanabe, and M Konishi, and M Yokoi, and R Kakehashi, and M Kaito, and M Kondo, and Y Hayashi, and T Jomori, and S Suzuki
Hepatitis C virus RNA in plasma and blood mononuclear cells in patients with chronic hepatitis C treated with alpha-interferon.
February 1995, Journal of medical virology,
Copied contents to your clipboard!